SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MAXM: Maxim Pharmaceuticals
An SI Board Since November 2000
Posts SubjectMarks Bans Symbol
35 8 0 MAXM
Emcee:  SI (no user) Type:  Unmoderated
Introduction Market Data Compact
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
10Maxim Scientists Present Preclinical Research Highlighting Ceplene Protection AgSemiBull-4/18/2002
9Maxim Announces Two Additional U.S. Patents for Apoptosis Screening Technology SemiBull-4/8/2002
8Maxim Pharmaceuticals and Celera Genomics Expand Collaborative Agreement SAN DISemiBull-3/18/2002
7particularly <i>drunk</i> rats...:o)SemiBull-3/4/2002
6<i>its drug Ceplene could completely reverse damage to the liver caused bynigel bates-3/4/2002
5Maxim says drug can stop liver damage from alcohol STOCKHOLM, March 4 (Reuters)SemiBull-3/4/2002
4Maxim Scientists Present Research At AACR Meeting Highlighting New Pro-Apoptoticnigel bates-2/13/2002
3Maxim Pharmaceuticals Announces Publication of Ceplene Phase 3 Trial Results in SemiBull-1/9/2002
2Monday October 22, 3:03 am Eastern Time Press Release SOURCE: Maxim PharmaceuticMiljenko Zuanic-10/22/2001
18th International Symposium on Hepatitis C and Related Viruses September 2-5, 20Miljenko Zuanic-9/4/2001
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News